Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

02/5
2019

Antibiotics or anti-inflammatory drugs may help combat lung cancer

from MIT News Bacteria promote lung tumor development, study suggests MIT cancer biologists have discovered a new mechanism that lung tumors exploit to promote their own survival: These tumors alter bacterial populations within the lung, pr…

01/28
2019

New Treatment Options for ROS1, BRAF, and NTRK Alterations in NSCLC

from OncLive The scope of targeted therapies has extended more in non–small cell lung cancer (NSCLC), especially with the recent FDA approval of larotrectinib (Vitrakvi) for patients with NTRK gene fusions irrespective of the primary tumor…

01/23
2019

Molecular profiling could catch lung cancer early and lead to new treatments

From Medical Express Molecular profiling to catch lung cancer early The world's first genetic sequencing of precancerous lung lesions could pave the way for very early detection and new treatments, reports a new study led by University Coll…

01/16
2019

New Protein Found Linked to Lung Cancer Treatment Resistance

From MedExpress Lung cancer remains a major cause of mortality across the globe, although we are gaining a deeper understanding of the genetic background behind this disease, including the mutations that promote it. Mutation in the gene EGFR…

01/16
2019

What happens when the doctor blames you for your own cancer?

How bias in the medical community hurts lung cancer patients. from The Washington Post Not long ago, I was working in a busy teaching hospital’s intensive-care unit, poring over EKGs, examining X-rays and reviewing medication orders. I re…

01/2
2019

Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis

from EurekAlert University of Colorado Study Patients now living a median 6.8 years: According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chan…

01/2
2019

Lung Cancer Deaths are 28 Percent Lower in California

From UC San Diego Health State’s long-term, aggressive tobacco control programs cited as primary reason Early adoption of tobacco control efforts in California led to fewer people ever smoking, reduced the amount used by those who do smok…

01/2
2019

First-Line Immunotherapy Combo Fails to Improve Survival in Lung Cancer Trial

From Specialty Pharmacy Times Clinical Trial results: First-line immunotherapy combo fails: New study shows that first-line immunotherapy that uses durvalumab (Imfinzi, AstraZeneca) or the combination of durvalumab and tremelimumab failed t…

12/8
2018

FDA Approves Atezolizumab Combination

from Business Wire FDA Approves Atezolizumab in Combination Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approvedatezolizumab (Tecentriq®), in combination with Avastin® (bevac…

12/8
2018

Policy changes needed for access to lung cancer treatments

from The Hill Advances in Lung Cancer Treatment Advances in treatment have completely transformed the way that Americans are living with lung cancer, something that was unthinkable even ten years ago. Since 2015, the U.S. Food and Drug Ad…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson